Results 101 to 110 of about 13,066 (196)
Table of Contents, Volume Six, 1970 [PDF]
Table of contents for MCV/Q, Medical College of Virginia Quarterly, 1970, Volume ...
core +1 more source
Background. Paroxysmal nocturnal hemoglobinuria is a rare clonal disease of the hematopoietic system, with the key manifestations of hemolytic anemia, a high thrombosis rate, and bone marrow failure.
V. D. Latyshev +6 more
doaj +1 more source
Paroxysmal nocturnal hemoglobinuria is a rare disease of the red blood cell membrane that renders it lyzable by the complement system, leading to chronic intravascular hemolysis. Renal hemosiderosis is a well-known complication of intravascular hemolytic
Deena T Boqari +6 more
doaj +1 more source
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematopoietic stem cell disease caused by abnormal expression of glycosylphosphatidylinositol (GPI) on the cell membrane due to mutations in the phosphatidylinositol glycan class A(PIGA ...
CHEN Miao +26 more
doaj +1 more source
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic acquired clonal stem cell disorder, typically manifesting hemolysis, pancytopenia and thrombosis in various organs. PNH-associated cutaneous thrombosis is extremely rare.
Fu-Nien Hsieh +2 more
doaj +1 more source
Key Clinical message Eculizumab in pregnancy has been reported to be effective in improving outcomes in patients with paroxysmal nocturnal hemoglobinuria. However, a cesarean section may result in surgery‐triggered hemolysis.
Dongping Li +8 more
doaj +1 more source
Hemolysis in runners as evidenced by low serum haptoglobin: Implications for preflight monitoring of astronauts [PDF]
Hematological parameters and serum haptoglobin were examined in 21 male employees of the Kennedy Space Center who were at 3 levels of physical activity: 7 subjects regularly ran more than 40 km (25 miles) per week (Group I); 7 ran 13 to 24 km (8 to 15 ...
Frey, Mary Anne Bassett +2 more
core +1 more source
Key Clinical Message Haploidentical hematopoietic stem cell transplantation (HSCT) with posttransplant cyclophosphamide is an alternative treatment for aplastic anemia–paroxysmal nocturnal hemoglobinuria (PNH) syndrome with poor prognostic factors ...
Kazuki Sakurai +6 more
doaj +1 more source
Quality-adjusted survival analysis shows differences in outcome after immunosuppression or bone marrow transplantation in aplastic anemia [PDF]
Bone marrow transplantation (BMT) and immunosuppression (IS) have improved the prognosis of aplastic anemia; both treatments have specific advantages and drawbacks but similar survival rates.
Favre, Geneviève +7 more
core

